SpringWorks Therapeutics (NASDAQ:SWTX) just reported results for the second quarter of 2024.
- SpringWorks Therapeutics reported earnings per share of -54 cents. This was above the analyst estimate for EPS of -$1.11.
- The company reported revenue of $59.73 million.
- This was 78.36% better than the analyst estimate for revenue of $33.49 million.